Insider

Alcon Inc

ALC Santé · 1 analyse

Ce qui a changé

Historique de la société

Octobre 2026

ALCON INC: 12 recorded developments from 5 official sources in 2026-10.

  • 2026-09-28: Attendees will have opportunities to engage with Alcon innovations through the WaterInnovations™ Immersive Experience, MARLO demonstrations and an Innovation Suite featuring Voyager™ DSLT and the Valeda® PBM device at Academy 2026. Source
  • 2026-09-28: The Innovation Suite will feature Voyager DSLT and Valeda PBM, giving optometrists an opportunity to learn about technologies supporting care for glaucoma and dry age-related macular degeneration patients. Source
  • 2026-09-28: Alcon helps more than 260 million people in over 140 countries and territories each year with eye conditions and employs more than 25,000 associates enhancing quality of life through innovative products and programs. Source
  • 2026-09-28: TRYPTYR (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease and should not be administered while wearing contact lenses; lenses may be reinserted 15 minutes following administration. Source
  • 2026-09-28: The Voyager DSLT device is an automated ophthalmic laser device for direct selective laser trabeculoplasty that uses a Q-switched, 3-ns pulse width, frequency-doubled Nd:YAG laser at 532 nm, directs a 400-μm beam to the limbus without contact, and uses image-processing and eye-tracking a Source
  • 2026-09-29: Featured innovations include the UNITY platform, highlighted by the new UNITY M ophthalmic microscope, along with Clareon PanOptix Pro, Clareon TruPlus IOLs, Valeda Photobiomodulation (PBM) and Voyager DSLT. Source
  • 2026-09-29: Alcon's more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Source
  • 2026-09-29: In July 2026, Alcon and Aravind launched the Aravind Retina Centre of Excellence in Coimbatore, India, a dedicated training facility designed to expand retina education, facilitate knowledge exchange and provide hands-on learning opportunities for Eye Care Professionals in India and beyo Source
  • 2026-09-29: In 2024, Alcon and Aravind launched the Global Centre of Excellence for advanced cataract surgery training, helping equip surgeons with the skills and technologies needed to deliver high-quality care. Source
  • 2026-10-01: Alcon (SIX/NYSE: ALC) announced new investigator-initiated clinical data demonstrating that SYSTANE® PRO Preservative-Free (PF) provided clinically comparable dry eye symptom relief to MIEBO^ (perfluorohexyloctane ophthalmic solution), meeting the study's primary endpoint of non-inferior Source
  • 2026-10-20: Alcon acquired Neurotech Pharmaceuticals, Inc. Source
  • 2026-10-20: Alcon's acquisition of Neurotech includes ENCELTO (revakinagene taroretcel-lwey), an encapsulated cell therapy intended for surgical intravitreal implantation. Source

Les synthèses mensuelles sont rédigées par l’IA à partir des rapports et sources officielles vérifiés de chaque mois (en anglais, tels qu’extraits), chaque ligne renvoyant à sa source ; les fils conducteurs regroupent les développements liés entre analyses grâce aux embeddings vectoriels (Amazon Titan Text Embeddings V2). Contexte provisoire, pas un conseil en investissement.

Pairs du secteur

Comparaison avec 36 entreprises suivies dans le secteur Santé (variation médiane du CA : +7,2% sur 1 an), d'après les données SEC XBRL.

EntrepriseDernier CACA sur 1 anMarge opérationnelle
Alcon Inc ALC———
Unitedhealth Group Inc UNH113 Md $-0,4%5,8%
Mckesson Corp MCK111 Md $+7,6%1,4%
CVS Health Corp CVS108 Md $+5,4%3,3%
Cigna Group CI73,7 Md $+5,6%3,3%
Cardinal Health Inc CAH67,5 Md $+5,5%1,1%
Elevance Health, Inc. ELV51,4 Md $+1,4%2,5%

Dernière période publiée par entreprise selon SEC CompanyFacts (XBRL). Les calendriers fiscaux peuvent différer.

Grands fonds (13F)

FondsActionsValeurVariation du nombre d’actionsTrimestre
Norges Bank (Norway's sovereign fund)10 976 697$741 431 995—T2 2026
Fidelity (FMR)7 567 130$489 960 885-1,3%T3 2026
D. E. Shaw & Co.2 918 650$188 982 588+57,1%T3 2026
Two Sigma Investments2 030 060$131 446 385+346,6%T3 2026
Citadel Advisors684 878$44 345 851+73,2%T3 2026
BlackRock638 773$41 360 589-1,8%T3 2026
Wellington Management114 082$7 375 467+1,4%T3 2026
Millennium Management106 204$6 876 709+470,6%T3 2026
Bridgewater Associates28 891$2 176 937—T1 2026
State Street6 123$396 4640,0%T3 2026

D’après les rapports trimestriels 13F-HR des grands fonds que nous suivons, tels que déposés. Les fonds déclarent jusqu’à 45 jours après la fin du trimestre : les positions ont pu changer depuis. Variation : par rapport au trimestre précédent du même fonds. Pas une recommandation.